This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Industry Stocks to Watch as Technology Expenses Take a Toll
by Debasmita Chatterjee
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Why Is Molina (MOH) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If You Invested $1000 in Molina a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Here's Why You Should Hold Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and well-performing Medicaid and Medicare segments poise it for growth.
Here's Why Molina (MOH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ensign Group (ENSG) Beats on Q1 Earnings, Hikes '23 EPS View
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter results benefit from growing skilled services revenues. Management estimates EPS of $4.64-$4.77 for this year, higher than the earlier mentioned $4.60-$4.74.
Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
Molina (MOH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Molina (MOH) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Molina (MOH) Q1 Earnings Beat Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 13.26% and 1.04%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth Group (UNH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 0.32% and 2.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Molina (MOH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Stocks to Watch Despite Elevated Tech Costs, Nursing Shortage
by Debasmita Chatterjee
Improved premiums cropping from a solid customer base might aid the Medical-HMO industry. However, an escalating expense level and an acute shortage of nurses are roadblocks. Stocks like UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Molina (MOH) Down 12.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet (THC) Q4 Earnings Beat on Ambulatory Care Strength
by Zacks Equity Research
Tenet Healthcare's (THC) bottom line deteriorates due to higher operating expenses, partially offset by an improving Ambulatory Care segment.
Encompass Health's (EHC) Shares Up 3% on Q4 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results reflect growing patient volumes and reimbursement rates. Management expects 2023 adjusted EPS within $2.87-$3.16, higher than $2.85 in 2022.
Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.
Here's What Key Metrics Tell Us About Molina (MOH) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Molina (MOH) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Molina (MOH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 0.99% and 4.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?